



Cancer Research

Latest Update 07/06/2026

Cancer

FY26 CDMRP program announcements:

Below is a list of the recently released CDMRP grant opportunities. Most of these require either a letter of intent or a pre-proposal (that is not particularly detailed). Those programs in “gray” have not yet been released. The Conafay Group is available to assist and guide you through the application process. To accomplish this, the Conafay Group (TCG) will need to see your pre-application or letter of intent on or before the dates listed on the Table. However, TCG is willing to discuss your ideas prior to submission to strengthen the proposal and make it more consistent with the goals of the Department of Defense. Please feel free to contact Evie Smith (esmith@conafaygroup.com) if you are interested in pursuing any of these opportunities. Dr. Qingzhao Yu (qyu@lsuhsc.edu) or Dr. Wayne Backes (wbacke@lsuhsc.edu) are also available to answer any questions that you might have.

Program	Website	Pre-Applica tion Format	Pre-Applica tion Draft Due to Conafa y	Pre-Applica tion Due	Full Propo sal Draft Due to Conaf ay	Full Propo sal Due
Alzheimer's	https://cdmrp.health.mil/funding/azrp	Pre-propos al	8-Jun	22-Jun	3-Sep	24-Sep

Amyotrophic Lateral Sclerosis	https://cdmrp.health.mil/funding/alsrp	Pre-proposal	10-Jun	24-Jun	9-Sep	30-Sep
Arthritis	https://cdmrp.health.mil/funding/atrp	Pre-proposal	8-Jun	22-Jul	1-Oct	22-Oct
Autism	https://cdmrp.health.mil/funding/arp	Pre-proposal	13-Jul	27-Jul	1-Oct	22-Oct
Bone Marrow Failure	https://cdmrp.health.mil/bmfrp					
Breast Cancer	https://cdmrp.health.mil/funding/bcrp	LOI	10-Jun	24-Jun	17-Jun	8-Jul
		Pre-proposal	29-May	12-Jun	9-Sep	30-Sep
Combat Readiness Medical	https://cdmrp.health.mil/crrp					
Duchenne Muscular Dystrophy	https://cdmrp.health.mil/dmdrp					
Epilepsy	https://cdmrp.health.mil/funding/erp	LOI	20-Jul	3-Aug	27-Jul	17-Aug
Hearing Restoration	https://cdmrp.health.mil/funding/hrrp	LOI	11-Aug	25-Aug	20-Aug	10-Sep
Joint Warfighter	https://cdmrp.health.mil/jwrrp					
Kidney Cancer	https://cdmrp.health.mil/kcrrp					
Lung Cancer	https://cdmrp.health.mil/funding/lcrp	LOI	4-Aug	18-Aug	12-Aug	2-Sep
		Pre-proposal	9-Jun	23-Jun	12-Aug	2-Sep

Lupus	https://cdmrp.health.mil/funding/lrp	LOI	15-Jul	29-Jul	29-Jul	19-Aug
Melanoma	https://cdmrp.health.mil/funding/mrp	LOI	8-Sep	22-Sep	23-Sep	14-Oct
		Pre-proposal	29-Jun	13-Jul	23-Sep	14-Oct
Military Burn	https://cdmrp.health.mil/funding/mbrp	Pre-proposal	23-Jun	7-Jul	30-Sep	21-Oct
Multiple Sclerosis	https://cdmrp.health.mil/funding/msrp	LOI	16-Jul	30-Jul	23-Jul	13-Aug
Neurofibromatosis	https://cdmrp.health.mil/nfnp					
Orthopaedic	https://cdmrp.health.mil/prorp					
Ovarian Cancer	https://cdmrp.health.mil/funding/ocrp	LOI	1-Sep	15-Sep	10-Sep	1-Oct
		Pre-proposal	29-Jun	13-Jul	10-Sep	1-Oct
Pancreatic Cancer	https://cdmrp.health.mil/funding/pcarp	LOI	2-Sep	16-Sep	16-Sep	7-Oct
		Pre-proposal	23-Jun	7-Jul	16-Sep	7-Oct
Parkinson's	https://cdmrp.health.mil/prp					
Peer Reviewed Cancer	https://cdmrp.health.mil/funding/prcrp	Pre-proposal	12-Jun	26-Jun	14-Sep	5-Oct
Peer Reviewed Medical	https://cdmrp.health.mil/funding/prmrp	LOI	2-Jul	16-Jul	9-Jul	30-Jul
		LOI	9-Jul	23-Jul	16-Jul	6-Aug
		Pre-proposal	9-Jul	23-Jul	1-Sep	22-Sep

Rare Cancers	https://cdmrp.health.mil/rcrp					
Prostate Cancer	https://cdmrp.health.mil/funding/pcrp	LOI	29-Jul	12-Aug	12-Aug	2-Sep
Traumatic Brain Injury & Psychological Health	https://cdmrp.health.mil/funding/tbiphrp	LOI	10-Sep	24-Sep	24-Sep	15-Oct
		Pre-proposal	29-Jun	13-Jul	24-Sep	15-Oct
Reconstructive Transplant Research	https://cdmrp.health.mil/rtrp					
Spinal Cord Injury	https://cdmrp.health.mil/funding/scirp	Pre-proposal	19-Jul	3-Aug	22-Oct	12-Nov
Tick Borne Disease	https://cdmrp.health.mil/funding/tbdrp	Pre-proposal	8-Jul	22-Jul	1-Oct	22-Oct
Toxic Exposures	https://cdmrp.health.mil/funding/terp	Pre-proposal	5-Aug	19-Aug	29-Oct	19-Nov
Tuberous Sclerosis Complex	https://cdmrp.health.mil/funding/tscrp	LOI	9-Jul	23-Jul	16-Jul	6-Aug
Vision	https://cdmrp.health.mil/funding/vrp	LOI	11-Aug	25-Aug	20-Aug	10-Sep
		Pre-proposal	14-Jul	28-Jul	22-Oct	12-Nov

- [Lung Cancer Research Foundation](#) (LCRF) Research Funding Opportunities
(Applicants may only apply for one LCRF grant per grant cycle):
 - **2026 LCRF | AstraZeneca Research Award on Strategies Using Patient Advocacy to Improve Outcomes in Small Cell Lung Cancer.** [Details.](#)

- LOI submission deadline: **July 15, 2026**
- Full proposal submission deadline: **October 5, 2026**
- **NIH**, Dissemination and Implementation Research in Health (**R01** Clinical Trial Optional) ([PAR-25-144](#)), (**R03** Clinical Trial Not Allowed) ([PAR-25-233](#)), (**R21** Clinical Trial Optional) ([PAR-25-143](#)). **Expiration Date: January 08, 2028.**
- **NCI, NIMHD, NIAAA**, Interventions to Address Disparities in Liver Diseases and Liver Cancer (**R01** – Clinical Trials Optional) ([PAR-25-299](#)). **Expiration Date: January 8, 2028.**
- **NIH, NCI**, Basic Research in Cancer Health Disparities (**R01** Clinical Trial Not Allowed) ([PAR-25-243](#)). **Expiration Date: January 8, 2028.**
- **NIH, NCI**, Basic Research in Cancer Health Disparities (**R21** Clinical Trial Not Allowed) ([PAR-25-244](#)). **Expiration Date: November 17, 2027.**
- **NCI**, Toward Translation of Nanotechnology Cancer Interventions (TTNCI; **R01** Clinical Trial Not Allowed) ([PAR-25-336](#)). **Expiration Date: November 16, 2027.**
- **NCI**, Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (**R01** Clinical Trial Optional) ([PAR-25-175](#)). **Expiration Date: January 08, 2028.**
- **NCI, NIAAA**, Population Approaches to Reducing Alcohol-related Cancer Risk (**R01** Clinical Trial Optional) ([PAR-25-221](#)). **Expiration Date: January 08, 2027.**
- **NCI**, Cancer Prevention and Control Clinical Trials Grant Program (**R01** Clinical Trial Required) ([PAR-25-167](#)). **Expiration Date: January 08, 2027.**
- **NCI**, Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (**R01** Clinical Trial Not Allowed) ([PAR-24-304](#)). **Expiration Date: October 15, 2026.**
- **NCI**, National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (**R01** Clinical Trial Required) ([PAR-25-081](#)). **Expiration Date: January 08, 2027.**
- **NCI**, Modular R01s in Cancer Control and Population Sciences (**R01** Clinical Trial Optional) ([PA-25-172](#)). **Expiration Date: January 08, 2028.**

- **NCI**, Molecular Imaging of Inflammation in Cancer (**R01** Clinical Trial Not Allowed) ([PAR-24-311](#)). Expiration Date: January 08, 2028.
- **NCI**, Mechanisms that Impact Cancer Risk after Bariatric Surgery (**R01** Clinical Trial Optional) [PAR-25-043](#), (**R21** Clinical Trial Not Allowed) [PAR-25-044](#). Expiration Date: January 08, 2028.
- **NIH**, Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (**R01** Clinical Trial Not Allowed) ([PAR-25-095](#)); (**R21** Clinical Trials Not Allowed) ([PAR-25-096](#)). Expiration Date: September 08, 2026.
- **NCI**, Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (**R01** Clinical Trial Optional) ([PAR-25-069](#)); (**R21** Clinical Trial Not Allowed) ([PAR-25-070](#)). Expiration Date: January 08, 2027.
- **NCI**, Exploratory Grants in Cancer Control (**R21** Clinical Trial Optional) ([PA-25-253](#)). Expiration Date: September 08, 2028.
- **NIH** Exploratory/Developmental Research Project Grant (**Parent R21** Clinical Trial Not Allowed) ([PA-25-304](#)). Expiration Date: January 8, 2028.
- **NIH** Exploratory/Developmental Research Project Grant (**Parent R21** Clinical Trial Required) ([PA-25-306](#)). Expiration Date: January 8, 2028.
- **NCI**, Cancer Prevention and Control Clinical Trials Planning Grant Program (**U34** Clinical Trials Optional) ([PAR-25-103](#)); (**R34** Clinical Trials Optional) ([PAR-25-104](#)). Expiration Date: October 26, 2027.
- **NCI** Pathway to Independence Award (**K99/R00** Clinical Trial Not Allowed) ([PAR-25-135](#)). Expiration Date: October 15, 2027.
- **NCI**, Assay Validation of High Quality Markers for Clinical Studies in Cancer (**UH2/UH3** Clinical Trial Not Allowed) ([PAR-25-074](#)), (**UH3** Clinical Trials Not Allowed) ([PAR-25-075](#)). Expiration Date: October 15, 2026.